Autoantibody Against Aldehyde Dehydrogenase 2 Could Be a Biomarker to Monitor Progression of Graves' Orbitopathy

Overview

Journal Graefes Arch Clin Exp Ophthalmol

Specialty Ophthalmology

Date 2018 Feb 5

PMID 29397435

Citations 10

Authors

Kai-Chun Cheng

Yu-Jen Wu

Kai-Hung Cheng

Kai-Yuan Cheng

Kuo-Jen Chen

Wen-Chuan Wu

Po-Yen Lee

Cheng-Hsien Chang

Affiliations

Soon will be listed here.

Abstract

Purpose: This study surveyed the novel autoantigens expressed in the orbital fat tissue of patients with Graves' orbitopathy (GO) and explored the possibility of the autoantibodies against novel autoantigens as biomarkers for GO.

Methods: We used immuno-proteomic methods to survey novel autoantigens expressed in the orbit fat tissue of GO patients and confirmed by enzyme-linked immunosorbent assay (ELISA).

Results: One protein spot (aldehyde dehydrogenase 2 (ALDH2)) revealed high reactivity with the GO serum than did the healthy control serum and was further verified by ELISA. We found that the plasma anti-ALDH2 antibody level was increased in GO patients compared to healthy control donors. In addition, anti-ALDH2 antibody level was correlated with GO activity classified by clinical activity score(r = 0.588, p < 0.001, using Pearson's correlation).

Conclusions: These increased levels of anti-ALDH2 antibody in GO serum suggested that ALDH2 could attribute target autoantigen in GO, and anti-ALDH2 autoantibody might serve as a biomarker for GO and help to predict disease activity.

Citing Articles

A combined transcriptomics and proteomics approach reveals S100A4 as a potential biomarker for Graves' orbitopathy.

Chng C, Lai O, Seah L, Yong K, Chung Y, Goh R Front Genet. 2024; 15:1342205.

PMID: 39359477 PMC: 11445072. DOI: 10.3389/fgene.2024.1342205.

Prediction models of intravenous glucocorticoids therapy response in thyroid eye disease.

Zhang H, Wu S, Hu S, Fan X, Song X, Feng T Eur Thyroid J. 2024; 13(4).

PMID: 39186944 PMC: 11378126. DOI: 10.1530/ETJ-24-0122.

Comparison of the correlation between serum autoantibodies against aldehyde dehydrogenase 2 and thyrotropin receptor in patients with Graves' ophthalmopathy.

Lin C, Chiu L, Lee P, Chen K, Cheng K Indian J Ophthalmol. 2024; 72(2):298-299.

PMID: 38273693 PMC: 10941939. DOI: 10.4103/IJO.IJO_673_23.

Predictive markers for anti-inflammatory treatment response in thyroid eye disease.

Zhang H, Fan J, Qu J, Han Q, Zhou H, Song X Front Endocrinol (Lausanne). 2023; 14:1292519.

PMID: 38111706 PMC: 10726127. DOI: 10.3389/fendo.2023.1292519.

Molecular Biomarkers in Thyroid Eye Disease: A Literature Review.

Ueland H, Neset M, Methlie P, Ueland G, Pakdel F, Rodahl E Ophthalmic Plast Reconstr Surg. 2023; 39(6S):S19-S28.

PMID: 38054982 PMC: 10697285. DOI: 10.1097/IOP.0000000000002466.

References

Greenfield N, Pietruszko R . Two aldehyde dehydrogenases from human liver. Isolation via affinity chromatography and characterization of the isozymes. Biochim Biophys Acta. 1977; 483(1):35-45. DOI: 10.1016/0005-2744(77)90005-5. View

Gianoukakis A, Khadavi N, Smith T . Cytokines, Graves' disease, and thyroid-associated ophthalmopathy. Thyroid. 2008; 18(9):953-8. PMC: 2879490. DOI: 10.1089/thy.2007.0405. View

Crabb D, Matsumoto M, Chang D, You M . Overview of the role of alcohol dehydrogenase and aldehyde dehydrogenase and their variants in the genesis of alcohol-related pathology. Proc Nutr Soc. 2004; 63(1):49-63. DOI: 10.1079/pns2003327. View

Perros P, Neoh C, Dickinson J . Thyroid eye disease. BMJ. 2009; 338:b560. DOI: 10.1136/bmj.b560. View

Mourits M, Prummel M, Wiersinga W, Koornneef L . Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol (Oxf). 1997; 47(1):9-14. DOI: 10.1046/j.1365-2265.1997.2331047.x. View

Hrda P, Sterzl I, Vana S, Novak Z, Matucha P, Kromminga A . [Endocrine orbitopathy and significance of autoantibodies against 1D protein]. Cas Lek Cesk. 2007; 146(3):273-7. View

Bahn R . Clinical review 157: Pathophysiology of Graves' ophthalmopathy: the cycle of disease. J Clin Endocrinol Metab. 2003; 88(5):1939-46. DOI: 10.1210/jc.2002-030010. View

Barrio-Barrio J, Sabater A, Bonet-Farriol E, Velazquez-Villoria A, Galofre J . Graves' Ophthalmopathy: VISA versus EUGOGO Classification, Assessment, and Management. J Ophthalmol. 2015; 2015:249125. PMC: 4553342. DOI: 10.1155/2015/249125. View

Kruit P, van der Gaag R, Broersma L, Kijlstra A . Autoimmunity against corneal antigens. I. Isolation of a soluble 54 Kd corneal epithelium antigen. Curr Eye Res. 1986; 5(4):313-20. DOI: 10.3109/02713688609020057. View

10.

Gerding M, van der Meer J, Broenink M, Bakker O, Wiersinga W, Prummel M . Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy. Clin Endocrinol (Oxf). 2000; 52(3):267-71. DOI: 10.1046/j.1365-2265.2000.00959.x. View

11.

Lahooti H, Parmar K, Wall J . Pathogenesis of thyroid-associated ophthalmopathy: does autoimmunity against calsequestrin and collagen XIII play a role?. Clin Ophthalmol. 2010; 4:417-25. PMC: 2874268. DOI: 10.2147/opth.s6534. View

12.

Lu C, Lin J, Huang H, Ko Y, Hsu J, Chen J . A panel of tumor markers, calreticulin, annexin A2, and annexin A3 in upper tract urothelial carcinoma identified by proteomic and immunological analysis. BMC Cancer. 2014; 14:363. PMC: 4039341. DOI: 10.1186/1471-2407-14-363. View

13.

Marchitti S, Brocker C, Stagos D, Vasiliou V . Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily. Expert Opin Drug Metab Toxicol. 2008; 4(6):697-720. PMC: 2658643. DOI: 10.1517/17425255.4.6.697 . View

14.

Swain M, Swain T, Mohanty B . Autoimmune thyroid disorders-An update. Indian J Clin Biochem. 2012; 20(1):9-17. PMC: 3454167. DOI: 10.1007/BF02893034. View

15.

Verhagen C, Mor F, Kipp J, de Vos A, van der Gaag R, Cohen I . Experimental autoimmune keratitis induced in rats by anti-cornea T-cell lines. Invest Ophthalmol Vis Sci. 1999; 40(10):2191-8. View

16.

Wall J, Lahooti H . Pathogenesis of thyroid eye disease--does autoimmunity against the TSH receptor explain all cases?. Endokrynol Pol. 2010; 61(2):222-7. View

17.

Edassery S, Shatavi S, Kunkel J, Hauer C, Brucker C, Penumatsa K . Autoantigens in ovarian autoimmunity associated with unexplained infertility and premature ovarian failure. Fertil Steril. 2010; 94(7):2636-41. PMC: 2948062. DOI: 10.1016/j.fertnstert.2010.04.012. View

18.

Kubota S, Gunji K, Ackrell B, Cochran B, Stolarski C, Wengrowicz S . The 64-kilodalton eye muscle protein is the flavoprotein subunit of mitochondrial succinate dehydrogenase: the corresponding serum antibodies are good markers of an immune-mediated damage to the eye muscle in patients with Graves' hyperthyroidism. J Clin Endocrinol Metab. 1998; 83(2):443-7. DOI: 10.1210/jcem.83.2.4553. View

19.

Tsui S, Naik V, Hoa N, Hwang C, Afifiyan N, Hikim A . Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease. J Immunol. 2008; 181(6):4397-405. PMC: 2775538. DOI: 10.4049/jimmunol.181.6.4397. View

20.

Chen C, Ferreira J, Gross E, Mochly-Rosen D . Targeting aldehyde dehydrogenase 2: new therapeutic opportunities. Physiol Rev. 2014; 94(1):1-34. PMC: 3929114. DOI: 10.1152/physrev.00017.2013. View